tiprankstipranks
Trending News
More News >
Kadimastem Ltd. (IL:KDST)
:KDST
Israel Market

Kadimastem (KDST) Price & Analysis

Compare
1 Followers

KDST Stock Chart & Stats


Financials

KDST FAQ

What was Kadimastem Ltd.’s price range in the past 12 months?
Kadimastem Ltd. lowest stock price was 430.00 and its highest was 2797.00 in the past 12 months.
    What is Kadimastem Ltd.’s market cap?
    Kadimastem Ltd.’s market cap is 112.75M.
      When is Kadimastem Ltd.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Kadimastem Ltd.’s earnings last quarter?
      Kadimastem Ltd. released its earnings results on Aug 23, 2021. The company reported -673.1 earnings per share for the quarter, missing the consensus estimate of N/A by -673.1.
        Is Kadimastem Ltd. overvalued?
        According to Wall Street analysts Kadimastem Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Kadimastem Ltd. pay dividends?
          Kadimastem Ltd. does not currently pay dividends.
          What is Kadimastem Ltd.’s EPS estimate?
          Kadimastem Ltd.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Kadimastem Ltd. have?
          Kadimastem Ltd. has 4,509,874 shares outstanding.
            What happened to Kadimastem Ltd.’s price movement after its last earnings report?
            Kadimastem Ltd. reported an EPS of -673.1 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Kadimastem Ltd.?
              Currently, no hedge funds are holding shares in IL:KDST

              Company Description

              Kadimastem Ltd.

              Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.
              Similar Stocks
              Company
              Price & Change
              Follow
              Compugen
              Enlivex
              Icl
              Can Fite Bio
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis